Comparing the current results to its competitors, Amarin Plcuk reported Revenue decrease in the 2 quarter 2026 year on year by -41.63 %, despite the revenue increase by the most of its competitors of 4.56 %, recorded in the same quarter.
Amarin Plcuk's Comment on Competition and Industry Peers
The company operates in a competitive environment where the use of AI and generative AI technologies by itself, third parties, and competitors may enhance operational efficiencies but also introduces risks such as flawed models, biased data, and potential legal liabilities. Competitors may implement AI technologies more rapidly or effectively, which could affect the company's market position. The company is subject to regulatory scrutiny concerning promotional claims for prescription products like VASCEPA, facing risks of whistleblower lawsuits and legal actions from competitors alleging mischaracterization of their products. Supply chain risks include potential competition from suppliers who may also supply competitors, including generic drug manufacturers, as well as disruptions due to manufacturing issues or loss of contract manufacturers. Third parties involved in regulatory and commercialization activities may have relationships with competitors, potentially influencing timelines and outcomes. Investigator-initiated trials (IITs) are conducted independently and are part of the broader research environment but are not directly controlled by the company.
December 16, 2024
Amarin s Breakthrough with VAZKEPA Reimbursement in Italy Amidst Market Challenges Amarin Corporation, recognized globally for its novel pharmaceutical advancements, has received a national reimbursement approval in Italy for its significant drug, VAZKEPA (icosapent ethyl). This approval marks a critical milestone for Amarin as it seeks to expand its market presence across Europe. VAZKEPA has been recognized for its potential to reduce cardiovascular risk in eligible high-risk patients. Italy s decision makes it the third country among the EU5 markets, alongside eight other European nations, to extend such reimbursement a testament to the clinical value perceived in VAZKEPA.The rise in cardiovascular conditi...
July 8, 2024
Amarin s Flagship Medication VASCEPA Receives Regulatory Approval in Mainland China, Paving the Way for Cardiovascular Risk ReductionIn a groundbreaking development, Amarin s strategic partner, EddingPharm, has received regulatory approval from the National Medical Products Administration (NMPA) for VASCEPA (Icosapent Ethyl) in Mainland China. The approval allows VASCEPA to be used as an adjunct to statin therapy for reducing the risk of cardiovascular events in adult patients with elevated triglyceride (TG) levels (150 mg/dL) and other high-risk characteristics, as demonstrated in the REDUCE-IT study.The decision by the NMPA highlights the significant potential of VASCEPA in helping to address the pressing ...
April 6, 2024
The groundbreaking REDUCE-IT trial has demonstrated the remarkable cardioprotective effects of VASCEPA/VAZKEPA (Icosapent Ethyl) in reducing cardiovascular events in high-risk patients. Recently published articles by leading cardiologists shed light on the utility of VASCEPA/VAZKEPA in specific patient subgroups and provide key insights into the impact of baseline High/Low Lp(a) and LDL-C levels. These findings have significant implications for the pharmaceutical company and its future strategies. is pleased to present a comprehensive analysis of two recently published articles that explore the efficacy of VASCEPA/VAZKEPA in high-risk cardiovascular disease patient subgroups and its utility in baseline High/...
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Sources:
Amarin Corp Plcuk’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Amarin Corp Plcuk versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
